Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
International Journal of Oncology|May 13, 2015
The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cellsTomas Groh, Jan Hrabeta, Mohammed Ashraf Khalil, et al.
International Journal of Molecular Sciences|April 3, 2021
MIAT Is an Upstream Regulator of NMYC and the Disruption of the MIAT/NMYC Axis Induces Cell Death in NMYC Amplified Neuroblastoma Cell LinesBarbara Feriancikova, Tereza Feglarova, Lenka Krskova, et al.
International Journal of Molecular Sciences|June 8, 2013
Serum metallothioneins in childhood tumours-a potential prognostic markerJarmila Kruseova, David Hynek, Vojtech Adam, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|April 11, 2019
Nanodrugs used in cancer therapyKaterina Kopeckova, Tomas Eckschlager, Jakub Sirc, et al.
Drug Metabolism Reviews|October 12, 2012
Metallothioneins and zinc in cancer diagnosis and therapySona Krizkova, Marketa Ryvolova, Jan Hrabeta, et al.
Cancer Letters|February 20, 2007
DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cellsJitka Poljaková, Eva Frei, Jacobo E Gomez, et al.
International Journal of Molecular Sciences|January 6, 2018
The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma CellsTereza Cerna, Jan Hrabeta, Tomas Eckschlager, et al.
Pharmacology & Therapeutics|August 16, 2011
Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advancesRene Kizek, Vojtech Adam, Jan Hrabeta, et al.
Biochemical Pharmacology|May 12, 2009
The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cellsJitka Poljaková, Tomás Eckschlager, Jan Hrabeta, et al.
Pageof 4